Latest Regulatory Compliance News

Aurumin Limited has had its trading suspension lifted following the announcement of proposed material transactions involving non-gold mineral rights at its key projects.

Gentrack reported a solid 9.8% revenue increase to NZ$112 million in HY25, driven by recurring revenue growth and international expansion, while net profit after tax surged 34.7%. The company’s outlook remains optimistic as it targets FY25 revenue above NZ$230 million and deeper market penetration across Asia, Europe, and the Middle East.

Liontown Resources has responded to an ASX query following a sharp rise in its share price and trading volume, denying any undisclosed information and confirming compliance with listing rules.

Celsius Resources has successfully completed the second tranche of its capital raising, issuing over 227 million shares and securing approximately A$1.75 million. The new shares are now trading on AIM, marking a significant step in the company’s funding strategy.

Resource Mining Corporation Limited (RMI) has responded to a sharp surge in its share price and trading volume, denying any undisclosed material information while pointing to ongoing copper-gold exploration activities at its Mpanda Project in Tanzania.

Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.

Southern Cross Gold has successfully closed the second tranche of its C$143 million private placement, securing nearly C$30 million to fund critical milestones at its Sunday Creek Gold-Antimony Project in Australia.

Future Metals NL has announced a partially underwritten entitlement offer aiming to raise approximately AUD 2.64 million to support development of its Eileen Bore Project and working capital needs. The offer opens to eligible shareholders on 15 May 2025 and closes on 30 May 2025.

EDU Holdings Limited plans to voluntarily delist from the ASX, citing low share liquidity and regulatory uncertainty in the international student market. The company proposes a substantial buy-back offer to provide shareholders with an exit opportunity ahead of delisting.

Emu NL has raised $300,000 through a placement of 17.6 million shares priced at 1.7 cents each, aiming to fund its exploration projects and support working capital needs.

Mayne Pharma has voluntarily withdrawn a speaker presentation for its contraceptive NEXTSTELLIS® following an FDA Untitled Letter concerning promotional claims. The company confirms this does not impact sales or its planned merger with Cosette.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.